广泛中和抗体用于人类免疫缺陷病毒治疗:理论广泛,现实狭窄
本文为观点类综述,简要回顾抗逆转录病毒治疗(ART)的现状与未满足需求,总结广泛中和抗体(bNAbs)作为抗逆转录病毒治疗及预防的研发进展与主要临床试验结果,并讨论其在治愈试验中的作用。作者结论认为,bNAbs在可被视为经典ART替代方案之前仍需大幅改进。
要点
- bNAbs用于HIV治疗仍受原发耐药检测、抗体联用数量未明、解剖储库穿透不足等限制。
- 作者比较经典ART与基于bNAbs的治疗的优缺点。
- 作者认为bNAbs仍需大幅改进才能考虑作为经典ART的替代。
核心结论
- 作者结论认为,广泛中和抗体在可被视为经典抗逆转录病毒治疗的替代方案之前仍需大幅改进。
研究设计与样本
- 本文为观点类文章,简要回顾抗逆转录病毒治疗现状、未满足需求及广泛中和抗体近期在HIV治疗中的可能作用。
主要发现
- 文章总结了bNAbs作为抗逆转录病毒治疗的研发进展、bNAbs用于HIV治疗与预防的主要临床试验结果及其在治愈试验中的作用。
局限性
- 原文列出的局限包括当前需要原发耐药检测、必须联用的抗体数量仍不明确、缺乏对解剖储库的穿透,以及它们在治愈研究中可能扮演的角色。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this viewpoint, we briefly review the status of antiretroviral therapy (ART), its unmet needs, and the role that broadly neutralizing antibodies (bNAbs) might have in the near future for the treatment of human immunodeficiency virus (HIV). We summarize advances in the development of bNAbs as antiretroviral therapy, the results of main clinical trials of bNAbs for HIV treatment and prevention, and its role in cure trials. The limitations of broadly neutralizing antibodies are the current need for primary resistance testing, the still unclear number of antibodies that must be combined, the lack of penetration in anatomical reservoirs, and the role they might play in cure studies. We compare the advantages and disadvantages of "classical ART" and therapy based on broadly neutralizing antibodies. We conclude that broadly neutralizing antibodies still need considerable improvements before they can be considered an alternative to classical ART.
引用
- Waters L, de Miguel-Buckley R, Poulin S, et al. Broadly Neutralizing Antibodies for Human Immunodeficiency Virus Treatment: Broad in Theory, Narrow in Reality. Clin Infect Dis. 2023. PMID: 36303321. doi:10.1093/cid/ciac835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。